- Tonix highlighted commercial rollout of fibromyalgia drug TONMYA, positioned as first FDA-approved treatment in more than 15 years.
- Net sales reached USD 1.4 million for period from Nov. 17 to Dec. 31, 2025.
- Launch metrics through Feb. 27, 2026 included more than 1,500 prescribers.
- Cash totaled about USD 210 million at Dec. 31, 2025.
- Tonix projected cash runway into Q1 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on March 31, 2026, and is solely responsible for the information contained therein.
Comments